Anthem Biosciences Q2 FY27 earnings call

Wed 4 Nov 202612:30 ISTANTHEM

In brief

Q2 FY27 revenue reached INR594 crores; management targeted double-digit FY27 growth and sustained margins.

Management's tone
Confident
What was said
Leaned positive
Guidance
Guidance held
Analyst pushback
Medium
Stock, next session
+3.96% (Nifty 50 +0.63%)
  • Q2 consolidated revenue from operations was INR594 crores, including INR509 crores from CRDMO and INR85 crores from Specialty Ingredients.
  • Management reported Q2 EBITDA of INR330 crores and a 50.6% margin, explicitly including INR59 crores of other income.
  • The pipeline reached 15 commercial and nine late-stage molecules after one program moved to commercial in Q2 FY27.
  • Management said it would try for double-digit FY27 revenue growth and expected further revenue catch-up in Q3 and Q4.
  • Management expects Specialty Ingredients to reach at least 20% of sales by end-FY27.

An AI read of the company's transcript · the filing

The numbers

The quarter, Q2 FY27

This quarterA year agoLast quarterMargin
Revenue₹594 cr+8.0%+42.0%
EBITDA (excl. other income)₹272 cr+24.6%+80.3%45.7% (39.6% a year ago)
Net profit₹0 cr——0% (0% a year ago)
EPS (₹)₹3.75+21.4%+76.1%

From the company's filed results for the quarter ended 30 Sept 2026 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.

Where management's figures differ from the filing

  • Q2 consolidated EBITDA: said INR330 crores EBITDA, including INR59 crores other income; filed ₹271.50 cr EBITDA excluding other income. Management explicitly included other income in its EBITDA, while the filed EBITDA measure excludes other income.
  • Q2 consolidated EBITDA margin: said 50.6%; filed 45.7% EBITDA margin excluding other income. The margin measures use different EBITDA definitions because management's EBITDA included other income.

What moved the numbers, as management explained it

  • Q2 revenue of INR594 crores comprised INR509 crores from CRDMO and INR85 crores from Specialty Ingredients, with CRDMO the larger contributor.
  • Management's 50.6% EBITDA margin reflected operating leverage: Q2 revenue ramped materially while costs stayed broadly unchanged, aided by cost discipline, yield optimisation and workforce productivity.
  • H1 procurement was 75%-78% domestic and 20%-21% China; management said lower Chinese sourcing and in-house manufacturing helped gross margin, alongside product mix.
  • INR59 crores of other income, up from INR48 crores, was included in management's INR330 crores Q2 EBITDA. (accounting)
  • Q2 revenue and margin performance followed catch-up after the lower-revenue Q1 base; management expects catch-up again in Q3 and Q4.
  • FX stayed within INR94.5-INR96.5, with no significant currency benefit expected in FY27 growth; any FX gain would sit in other income.

The numbers management led with

  • Unit 4 Phase 1 capex: Close to INR1,200 crores over the next two years; guidance remains intact.
  • Unit 4 Phase 1 footprint and scale: 30-acre facility; Phase 1 setup equivalent to the combined setup of Units 1, 2 and 3.
  • Commercial and late-stage molecule counts: 15 commercial molecules and nine late-stage molecules.
  • Asset turns: Currently about 1.2x-1.3x; aspirational 1.5x over the next year.

Guidance

Guidance on this call

WhatForWhat management said
Consolidated revenue growthFY27Management said it would try for double-digit consolidated revenue growth in FY27.
Unit 4 Phase 1 capexFY27-FY28Unit 4 Phase 1 capex remains close to INR1,200 crores over the next two years.
EBITDA margin including other incomeFY27Sustain FY26's EBITDA margin of about 43%, including other income.
Specialty Ingredients share of salesFY27Specialty Ingredients to be at least 20% of sales by end-FY27.
Q3-Q4 revenue catch-upH2 FY27Revenue catch-up is expected in Q3 FY27 and Q4 FY27.
Late-stage programs moving to commercial (CRDMO)FY27At least a few late-stage programs may become commercial in FY27.
Asset turnsFY28Move toward an aspirational 1.5x asset-turn level over the next year.
Late-stage programs moving to commercial (CRDMO)FY28-FY29Some late-stage programs may become commercial over the next 18-24 months.
Unit 4 Phase 1 capex allocation to biologyFY27-FY28At least 30%-35% of Unit 4 capex is allocated to biology; the rest to chemistry.
Unit 4 startFY28Unit 4 is expected to start around March 2028.
Contribution from newly commercialized molecules (CRDMO)FY28-FY31Newly commercialized molecules should make meaningful contributions over the next three to four years.
Commercialized molecule revenue growth (CRDMO)—Revenue growth from existing commercial molecules should mirror the molecules' market growth.

What changed since the Wed 22 Jul 2026 call

WhatOn the Wed 22 Jul 2026 callOn this call
FY27 revenue growth (raised)Business was expected to grow in line with historical YoY performance; no specific FY27 percentage was issued.Management said double-digit FY27 revenue growth would be tried, with catch-up planned in Q3 and Q4.
Q2 recovery (achieved)Q1 FY27 revenue was Rs 418 cr, down about 25% YoY on customer delivery timing; recovery was expected from Q2.Q2 revenue reached INR594 crores, and management described the quarter as a catch-up after the low Q1.
Commercial pipeline count (achieved)The pipeline had 14 commercial and 10 late-stage molecules.The pipeline had 15 commercial and nine late-stage molecules; one program moved to commercial in Q2 FY27.
Unit 4 Phase 1 capex (held)FY27 capex was ~Rs 700 cr; Unit 4 Phase 1 was ~Rs 1,200 cr, roughly 50-50 across FY27 and FY28.Management said capex guidance was intact and Unit 4 Phase 1 remained close to INR1,200 crores over the next two years.
FY27 margin objective (held)Q1 EBITDA margin was 39.6%; management prioritized defending industry-leading EBITDA/PAT margins.Management said FY26's EBITDA margin of about 43%, including other income, is sustainable in FY27.
Specialty Ingredients sales mix (new)Specialty Ingredients had no stated sales-mix target on the prior call.Management expects Specialty Ingredients to be at least 20% of sales by end-FY27.
FY27 order-book visibility (not repeated)Order book had 60% visibility for FY27 across the whole business.Not mentioned
FY27 effective tax rate (not repeated)FY27 tax rate was guided at 25-25.5% as Neo Anthem turned break-even to profitable.Not mentioned

Guided on earlier calls, and what was filed

WhatForGuidedFiled
EBITDA marginFY26at least 38% (on the Q1 FY26 call)38.1%, within the range
EBITDA margin (normalized, excl FX)FY2636–37% (on the Q2 FY26 call)38.1%, above the range

Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.

The business

By business

CRDMO

Q2 revenue was INR509 crores and H1 revenue INR850 crores. Management said 65% of the business was commercial manufacturing, with 20% split between R&D and development; 15 molecules were commercial and nine late-stage.

Q2 revenue INR509 crores · H1 revenue INR850 crores · Commercial manufacturing 65% of business · R&D and development supplies together 20% of business · Commercial molecules 15 · Late-stage molecules 9 · Big Pharma customers 8-9 · Biotech projects over 100

Outlook: Management expects strong underlying demand, double-digit FY27 revenue growth and Q3-Q4 catch-up, while sustaining FY26-level EBITDA margins.

Specialty Ingredients

Q2 revenue was INR85 crores and H1 revenue INR162 crores. Management said the segment was muted by strong CRDMO sales, remained profitable and did not disclose a margin split.

Q2 revenue INR85 crores · H1 revenue INR162 crores · Target share of sales at least 20%

Outlook: By end-FY27, management expects Specialty Ingredients to be at least 20% of sales; margins were described as in line and sufficiently high.

Peptides, oligonucleotides, RNAi and ADCs

Management said capabilities in peptides, oligonucleotides, RNAi and high-potency ADCs had progressed from lab scale to commercial scale, with early-stage programs and Unit 4 investments supporting expansion.

New-tech operating history 10-plus years

Outlook: No FY31 revenue share was quantified; management said new-technology programmes would move toward commercialisation over the next four years.

Balance sheet, capex and funding

  • The net cash position was INR1,534 crores at September 30, 2026.
  • Capex guidance for the next two years, largely Unit 4, remained close to INR1,200 crores; Phase 1 guidance stayed intact.
  • At least 30%-35% of Unit 4 capex was expected to go to biology, with the rest in chemistry.
  • Unit 4 was expected to start around March 2028; commissioning and regulatory approvals were expected to take additional time.

The industry, as management sees it

Management sees biotech funding as recovering but uneven: RFP/RFQ inflows have improved, yet geopolitical uncertainty has left customers uneasy, and M&A remains a route to commercial scale for late-stage biotech assets. AI is described as a highly uncertain industry force that could generate more molecules and therefore more outsourced development and manufacturing work.

Risks management named

  • Geopolitical uncertainty has left biotech customers uneasy despite improving RFP and RFQ inflows.
  • Biotech funding recovery remains uneven, making project timing and order conversion less predictable.
  • Residual China sourcing remains about 20%-21% of procurement despite expanded domestic suppliers.
  • Clinical failures or delays could prevent late-stage programs from converting to commercial supply.
  • AI-driven drug discovery remains highly uncertain, despite management expecting more outsourced work.
  • Unit 4 commissioning, approvals and ramp-up will take time before asset turns reach the 1.5x aspiration.

Q&A

Q&A centered on whether high margins are sustainable, Unit 4 capex and ramp economics, conversion of late-stage programs, and the mix of new modalities. Management was most guarded on molecule-specific forecasts, FY27 revenue, FY31 new-technology contribution and Unit 4 asset-turn timing, citing confidentiality, board approval and the need to commission facilities. Pushback was measured; management generally clarified the investment case or declined to speculate rather than disputing the core bullish setup.

Not answered directly

  • Constant-currency contribution to quarterly and full-year growth
  • Formal FY27 revenue guidance
  • Molecule-specific indication, ramp and peak-sales forecasts
  • Geographic growth attribution
  • Post-FY28 Phase 2 capex and its formal allocation
  • Number of late-stage programs converting to commercial supply
  • FY31 revenue contribution from new technologies
  • Unit 4 timeline to 1.5x asset turns

Asked for a number, answered without one

  • FY27 full-year revenue: Management declined to provide a full-year number but said double-digit growth would be tried, with catch-up in Q3 and Q4.
  • Newly commercial molecule ramp: Management declined to disclose the indication or peak sales because of customer contracts, saying only that prospects were good in a chronic-care category.
  • Phase 2 capex after FY28: Management said no guidance would be given until board approval, while noting Phase 2 could be similar in size to Phase 1.
  • Late-stage commercialisation count: Management said trial outcomes drive timing and it was difficult to put a number on expectations; only a few might commercialize this financial year.
  • New-technology revenue share: Management said it had not calculated the share and could not predict what percentage of revenue would come from new-age technology.
  • Specialty Ingredients segment margins: Management said it does not disclose segment margins, but described Specialty Ingredients as profitable and said overall margins had improved.
  • Unit 4 asset-turn timeline: Management said it is a longer-term question tied to commissioning and approvals, and it would discuss Unit 4 asset turns after commissioning starts.
  • H1 geographic growth split: Management said geography was not important, that Anthem serves global customers, and that it does not track growth by destination.

Every question, with its answer

  1. 1. Customer positioning

    Akash, Individual Investor

    Question. For complex or technically challenging molecules, how have customer expectations evolved, is Anthem increasingly the customer's first-choice solution partner, and what distinguishes Anthem from peers?

    Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Ajay said customers increasingly view Anthem as a solution provider rather than just a contract researcher or manufacturer. He said Anthem differentiates through intellectual contribution, multiple technical options and IP creation for complex molecules, supported by a technology-driven track record.

    Follow-up. Given geopolitical conditions and dependence on specialized enzymes, biocatalysts and other critical inputs, is Anthem largely self-sufficient and backward integrated?

    Answer. Ajay said Anthem is largely self-sufficient in enzymes and fermentation-based solutions once programs mature, though it tests different sources in early development. Backward integration reduces reliance on overseas supply chains and supports competitive cost of goods.

  2. 2. Pipeline conversion

    Gourav Bhama, JM Financial

    Question. Commercial molecules increased from 14 to 15 while late-stage molecules declined from 10 to nine: had one program moved into commercialization, and what are its indication, ramp-up and peak-sales prospects?

    Answer, Gawir Baig and Ajay Bhardwaj, Chief Financial Officer and Managing Director and Chief Executive Officer. Gawir confirmed one late-stage program was approved in Q2 FY27, taking the portfolio to 15 commercial and nine late-stage molecules. He said it is a chronic-care opportunity from an emerging-biotech customer, but declined indication and peak-sales details; Ajay cited contractual confidentiality.

    Follow-up. Has the revival in biotech funding increased RFP/RFQ inflows or the development pipeline?

    Answer. Ajay said RFP/RFQ inflows had improved in the recent quarter, but described biotech funding as a mixed bag because geopolitical uncertainty had left customers uneasy.

    Not answered directly.

  3. 3. Revenue mix, sourcing and concentration

    Sidharth Negandhi, CWC

    Question. What is the revenue split across the US, Europe and rest of world; how does early-stage research compare with development and commercial manufacturing; has China supply reliance fallen; and how concentrated are revenue in the top five and top ten customers?

    Answer, Gawir Baig, Chief Financial Officer. Gawir said about 84% of revenue was international and 16% India; within international revenue, the US was 22%-24%, Europe about 60%-plus and ROW 1%-2%. He described the mix as broadly 85% CRDMO and 15% Specialty Ingredients, with about 65% commercial manufacturing and about 20% combined R&D and development supplies. Domestic procurement was 75%-78% and China 20%-21%, versus reliance on one Chinese vendor earlier. Top five customers were about 50%-odd of business and top ten about 80%-odd.

    Follow-up. Which geography grew faster in H1, given Europe and US contributions to CRDMO growth?

    Answer. Ajay said shipment destination is less informative because Anthem serves global big pharma and products are distributed globally. He declined to frame growth by destination geography, saying the company is global.

    Not answered directly.

  4. 4. Currency impact

    Vijay Shah, Prudential Global Investment Management

    Question. Of the quarter's 8% revenue-from-operations growth, how much came from currency, and is most full-year growth likely ex-currency?

    Answer, Gawir Baig and Ajay Bhardwaj, Chief Financial Officer and Managing Director and Chief Executive Officer. Gawir said the rupee stayed in a narrow INR94.5-INR96.5 range and Anthem does not track constant-currency growth, so he could not isolate the currency contribution. He expected currency to remain broadly range-bound, with any benefit appearing in FX gains within other income rather than operating growth.

    Follow-up. Is the year's capex guidance unchanged?

    Answer. Gawir said Phase 1 guidance was intact at close to INR1,200 crores for Unit 4 over the next two years. The 30-acre facility would equal the combined Phase 1 setup of Units 1-3; a comparable Phase 2 would follow later.

    Not answered directly.

  5. 5. Phase 2 capex and gross margin

    Roni Naik, Arete Group Family Office

    Question. What capex is likely after FY28 for Unit 4 Phase 2, and did the 3% gross-margin improvement reflect reduced Chinese procurement?

    Answer, Gawir Baig and Ajay Bhardwaj, Chief Financial Officer and Managing Director and Chief Executive Officer. Gawir said no formal post-FY28 guidance can be given until board approval, although Phase 2 could be similar in scale to Phase 1. He attributed margin improvement to reduced Chinese sourcing, in-house manufacturing and a favorable customer and product shipment mix.

    Follow-up. How many of the 15 commercial and nine late-stage programs sit in RNAi, oligonucleotides, peptides and ADCs; are peptides limited to GLP-1; and how would Unit 4 capex split between NCE and NBE?

    Answer. Management said the portfolio includes RNAi, peptides, oligonucleotides and high-potency ADC programs, with many newer projects still early stage and requiring six to eight years to reach Phase 3. Peptides also address oncology and immunology beyond GLP-1. At least 30%-35% of Unit 4 capex should go to biology, with the rest chemistry, but the split remains demand-driven and fungible.

    Not answered directly.

  6. 6. Margin sustainability

    Anish, ICICI Life

    Question. What drove the margin uptick, and should investors assume these levels for coming quarters?

    Answer, Gawir Baig and Ajay Bhardwaj, Chief Financial Officer and Managing Director and Chief Executive Officer. Gawir said Q2 operating leverage came from a sizable revenue ramp against a broadly unchanged cost base. He noted Q2 EBITDA margin was about 50% versus about 43% for FY26 including other income, but declined to guide a 50% level; the FY26-comparable level was viewed as sustainable, and Ajay reiterated confidence.

    Follow-up. What FY27 revenue growth should investors work with after H1 declined 7%, given CRDMO lumpiness?

    Answer. Gawir declined to give a full-year revenue number, but said Anthem would try to deliver double-digit growth. He expects catch-up in Q3 and Q4 and expressed confidence in EBITDA and PAT growth from the superior margin profile.

    Not answered directly.

  7. 7. New molecule contribution and patent runway

    Bansi Desai, JP Morgan

    Question. Over a three-to-four-year horizon, how meaningful could newly commercialized molecules become, and can they offset patent expiries on existing key molecules?

    Answer, Ajay Bhardwaj and Gawir Baig, Managing Director and Chief Executive Officer and Chief Financial Officer. Ajay said the first relevant patent expiry is in 2032 and expects the five molecules commercialized over the last 18 months to contribute meaningfully over three to four years. Their combined estimated market potential was described as above $10 billion, with acquisitions by big pharma supporting supply demand.

    Follow-up. How many are APIs versus advanced intermediates, do you have preferred-supplier status, and how many of the nine late-stage programs should commercialize in one to two years?

    Answer. Gawir said the five are an equal mix of APIs and advanced intermediates. Ajay said Anthem is currently the only supplier with no technology transfer, although big pharma will likely add a second source. Trial outcomes are expected over 18-24 months; a few may become commercial in FY27, but no reliable conversion count was given.

    Not answered directly.

  8. 8. Specialty Ingredients outlook

    Isha, Invest Yadnya

    Question. What is the outlook and margin profile for Specialty Ingredients, and what structural sales mix does management want to maintain?

    Answer, Ajay Bhardwaj, Managing Director and Chief Executive Officer. Ajay said Specialty Ingredients should be at least about 20% of sales by FY27 year-end, acting as a backstop against lumpy CRDMO revenue. A strong CRDMO quarter muted the segment; management said its margins remain profitable and in line with the company, but did not disclose a separate margin.

    Partly answered.

  9. 9. US go-to-market, AI and Unit 4 returns

    Sidharth Negandhi, CWC

    Question. What advantages come from the US partnership-led go-to-market; how is biotech versus big pharma revenue evolving amid funding and M&A trends; could AI displace demand; and what new-technology revenue and Unit 4 asset turns should investors expect?

    Answer, Ajay Bhardwaj and Gawir Baig, Managing Director and Chief Executive Officer and Chief Financial Officer. Ajay described the Davos partnership as a differentiated, transparent US route to market that supplies local commercial and logistics support without building an equivalent sales force directly. He expects biotech M&A to continue and said more than 100 biotech projects create optionality; AI remains highly uncertain but could generate more molecules and outsourced work. Gawir said FY31 new-tech revenue cannot yet be predicted. Asset turns are 1.2x-1.3x currently, with a 1.5x aspiration over the next year, while Unit 4 starts around March 2028 and will take time to ramp.

    Follow-up. Will the INR1,200-crore Unit 4 reach 1.5x asset turns, and over what period?

    Answer. Gawir said it will require commissioning and approvals, so no timeline was given. Asset-turn guidance for Unit 4 would be revisited once the facility starts operating; the immediate focus is getting it commissioned.

    Not answered directly.

  10. 10. Commercial portfolio economics

    Saion Mukherjee, Nomura

    Question. Are the older commercial molecules still growing and how much headroom remains; will new products generate higher revenue per molecule than the existing base; and why has traction been limited for lateral or second-source contracts?

    Answer, Ajay Bhardwaj and Gawir Baig, Managing Director and Chief Executive Officer and Chief Financial Officer. Ajay said nearly all older molecules are still growing, with the first patent expiry in 2032 and some as late as 2037-2040; share gains could make Anthem grow faster than the underlying molecule. For new programs, he cited peak sales of roughly $1 billion-$5 billion each and about $10 billion in aggregate, while expecting average per-molecule revenue to be similar to the existing base, with upside for large indications and doses.

    Follow-up. What prevents greater traction in lateral contracts?

    Answer. Ajay said existing customers are entrenched with qualified suppliers and switching is difficult, so new second sources ramp slowly. Anthem supplying samples and completing qualification is a positive precursor, and an approved second source can scale rapidly if the incumbent falters.

    Partly answered.

  11. 11. Big pharma relationships and capability expansion

    Amey Chalke, JM Financial

    Question. What must Anthem do to become a preferred supplier to big pharma CDMO customers, and which capability white spaces should it address over the next four to five years versus global peers?

    Answer, Gawir Baig and Ajay Bhardwaj, Chief Financial Officer and Managing Director and Chief Executive Officer. Gawir said Anthem already works with eight to nine big pharma companies, retained relationships after eight or nine biotech customers were acquired, and is also winning direct programs. Ajay said capability expansion will cover biologics manufacturing and fill-finish, Unit 4 oligonucleotide capacity, oncology expansion and cybersecurity. Investment decisions will remain guided by customer programs rather than fixed five-year forecasts.

What was said

Topic by topic, in the order it was spoken

Call introduction and forward-looking notice · Radhika Kedia (Investor Relations)

  • Radhika Kedia welcomed participants and directed them to the financial results available under the company's Investor tab.
  • She introduced CEO Ajay Bhardwaj and CFO Gawir Baig and outlined the prepared-remarks and Q&A format.
  • A standard notice warned that forward-looking statements were subject to risks and that the company had no obligation to update them.

Q2 FY27 financial performance · Ajay Bhardwaj (CEO)

  • Consolidated revenue from operations was INR594 crores in Q2 FY27.
  • CRDMO contributed INR509 crores and Specialty Ingredients contributed INR85 crores.
  • EBITDA was INR330 crores at a 50.6% margin; Q2 FY27 included INR59 crores of other income versus INR48 crores a year earlier.
  • PBT was INR296 crores and PAT was INR211 crores, with PAT margin of 32.04%.

H1 FY27 financial performance · Ajay Bhardwaj (CEO)

  • H1 FY27 consolidated revenue from operations was INR1,012 crores.
  • CRDMO and Specialty Ingredients contributed INR850 crores and INR162 crores, respectively.
  • EBITDA was INR506 crores at a 46.2% margin, including INR84 crores of other income versus INR70 crores in H1 FY26.
  • PAT was INR331 crores, with PAT margin of 30.2%.

Profitability, cash and operating discipline · Ajay Bhardwaj (CEO)

  • Net cash stood at INR1,534 crores as of September 30, 2026.
  • Management attributed year-on-year margin expansion to strict cost-efficiency, yield-optimization and workforce-productivity discipline.
  • The CEO said the company had further solidified what it described as industry-leading margins.

Demand and full-year outlook · Ajay Bhardwaj (CEO)

  • Underlying demand remained strong.
  • Management expressed confidence in sustaining growth and creating long-term stakeholder value.
  • The company said it was well positioned to maintain its current performance through the year.

In their words

We have further solidified our industry-leading margins and are well-positioned to sustain this performance for the whole year.
Mr. Ajay Bhardwaj (Managing Director and Chief Executive Officer, Anthem Biosciences Limited)
As we have said, we promise we will be delivering good results by the end of the year, and we are on track to do that.
Mr. Ajay Bhardwaj (Managing Director and Chief Executive Officer, Anthem Biosciences Limited)
At the moment, we enjoy the only supplier status.
Mr. Ajay Bhardwaj (Managing Director and Chief Executive Officer, Anthem Biosciences Limited)

To check next time

What management committed to on this call, or the dates they gave.

  • Q3 revenue catch-up after the low Q1 base.
  • Q4 revenue catch-up and delivery of double-digit FY27 revenue growth.
  • Specialty Ingredients reaching at least 20% of FY27 sales by year-end.
  • EBITDA margin holding at about the FY26 level of 43%, including other income.
  • Unit 4 progress toward a start around March 2028 and subsequent commissioning.
  • Asset turns moving from about 1.2-1.3x toward the aspirational 1.5x over the next year.

Transcript

Read along with the recording

The whole call, 225 lines from 15 speakers over 1:00:15. Click any line to hear it, jump to the Q&A, or find a word. Free with an account.

Sign up freeLog in

The stock after the call

After the callCloseStockNifty 50
Next session Wed 4 Nov 2026₹888.30+3.96%+0.63%
5 sessions Mon 9 Nov 2026₹958.15+12.14%+5.18%

From the close of Tue 3 Nov 2026, ₹854.45: the last close before the call, which began at 12:30 IST. Adjusted daily closes; the move includes everything else that happened in those sessions.

Anthem Biosciences's other calls